As observed in ALK rearrangements, ALK point mutations have been described in number of cancers (i.e., anaplastic thyroid cancer [ATC], IMT and NSCLC), although less frequently than in neuroblastoma (Table 1). This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.